Natural Potential Inhibitors for Covid 19 – An Insilico Approach
-
Published:2021-09-14
Issue:
Volume:
Page:4913-4919
-
ISSN:0974-360X
-
Container-title:Research Journal of Pharmacy and Technology
-
language:en
-
Short-container-title:RJPT
Author:
Arockia Raj A. Anto1, J. Vinnarasi2
Affiliation:
1. Department of Chemistry, St. Xavier’s College (Autonomous), Palayamkottai, Tamil Nadu, India – 627002. 2. Department of Chemistry, The Standard Fireworks Rajaratnam College for Women (Autonomous), Sivakasi, Tamil Nadu, India – 626123.
Abstract
In 2019 severe acute respiratory syndrome (SARS) - associated with coronavirus is a new highly pathogenic human coronaviruses that emerged in china and has quickly spread all over the world. The mortality rate is about 26% globally. This has resulted in an urgent need to identify antiviral drugs that are active against SARS-Covid -19. Several compounds extracted from natural product and herbs exhibit antiviral activity. In the present study, eight compounds from natural products and five antiviral drugs have selected and docked against SARS-CoV-2. Curcuminoid are chief constituent of turmeric, has been used as a food additive and herbal increment due to its potential medicinal behavior. Curcumin has shown better antiviral effect against dengue, hepatitis C, zika and chikungunya viruses earlier. The molecular docking for exploring the binding abilities between naturally obtained known compounds comparable with Oseltamivir, Remdesivir, hydroxychloroquine, Zanamivir and Ribavirin against SARS-CoV-2, whose results may be used to design potential drug to meet out the need of the hour. The results showed that bismethoxycurcumin, demethoxycurcumin and gedunin have comparable high binding pose energies against SARS-CoV-2. We anticipate that these molecules may lead to the design or discovery of new effective actions for SARS-CoV-2.
Publisher
A and V Publications
Subject
Pharmacology (medical),Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
Reference68 articles.
1. World Health Organization. Communicable Disease Surveillance and Response. Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003, 2003 2. Drosten C, Gunther S, Preiser W, van der Werf S, Brodt HR, Becker S, Rabenau H, Panning M, Kolesnikova L, Fouchier R A, Berger A, Burguiere A M, Cinatl J, Eickmann M, Escriou N, Grywna K, Kramme S, Manuguerra JC, Muller S, Rickerts V, Sturmer M, Vieth S, Klenk HD, Osterhaus AD, Schmitz H, Doerr HW. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med. 2003; 348:1967. 3. Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, Emery S, Tong S, Urbani C, Comer JA, Lim W, Rollin PE, Dowell SF, Ling AE, Humphrey CD, Shieh WJ, Guarner J, Paddock CD, Rota P, Fields B, DeRisi J, Yang JY, Cox N, Hughes JM, LeDuc JW, Bellini WJ, Anderson LJ. SARS Working Group, A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med. 2003; 348: 1953. 4. Kuiken T, Fouchier RA, Schutten M, Rimmelzwaan GF, van Amerongen G, van Riel D, Laman JD, de Jong T, van Doornum G, Lim W, Ling AE, Chan PK, Tam JS, Zambon MC, Gopal R, Drosten C, van der Werf S, Escriou N, Manuguerra JC, Stohr K, Peiris JS, Osterhaus AD. Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet, 2003; 362 (9380): 263. 5. Peiris JS, Lai ST, Poon LL, Guan Y, Yam LY, Lim W, Nicholls J, Yee WK, Yan WW, Cheung MT, Cheng VC, Chan KH, Tsang DN, Yung RW, Ng TK, Yuen KY. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet. 2003; 361: 1319.
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|